Organigram Global Inc. (OGI)
NASDAQ: OGI · Real-Time Price · USD
1.215
-0.010 (-0.82%)
Aug 18, 2026, 1:22 PM EDT - Market open
Organigram Global Revenue
Organigram Global had revenue of 105.78M CAD in the quarter ending June 30, 2026, with 49.43% growth. This brings the company's revenue in the last twelve months to 309.18M, up 38.14% year-over-year. In the fiscal year ending September 30, 2025, Organigram Global had annual revenue of 259.18M with 62.15% growth.
Revenue (ttm)
309.18M CAD
Revenue Growth
+38.14%
P/S Ratio
0.80
Revenue / Employee
276,049 CAD
Employees
1,120
Market Cap
173.55M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 259.18M | 99.34M | 62.15% |
| Sep 30, 2024 | 159.84M | -1.80M | -1.11% |
| Sep 30, 2023 | 161.64M | 15.83M | 10.86% |
| Aug 31, 2022 | 145.81M | 66.65M | 84.19% |
| Aug 31, 2021 | 79.16M | -7.63M | -8.79% |
| Aug 31, 2020 | 86.80M | 6.38M | 7.94% |
| Aug 31, 2019 | 80.41M | 67.98M | 546.98% |
| Aug 31, 2018 | 12.43M | -377.00K | -2.94% |
| Aug 31, 2017 | 12.81M | 550.75K | 4.49% |
| Aug 31, 2016 | 12.26M | 11.27M | 1,142.07% |
| Aug 31, 2015 | 986.68K | - | - |
| Feb 28, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Emergent BioSolutions | 770.20M |
| Organogenesis Holdings | 457.45M |
| Aurora Cannabis | 221.16M |
| Akebia Therapeutics | 219.06M |
| Lifecore Biomedical | 129.46M |
| ADC Therapeutics | 79.58M |
| Journey Medical | 68.18M |
| SIGA Technologies | 53.66M |
OGI News
- 7 days ago - Organigram Global Q3 Earnings Call Highlights - MarketBeat
- 7 days ago - Organigram Global Earnings Call Transcript: Q3 2026 - Transcripts
- 7 days ago - Organigram Global Earnings release: Q3 2026 - Filings
- 7 days ago - Organigram Global Registration statement: Q3 2026 - Filings
- 7 days ago - Organigram Global Registration statement: Q3 2026 - Filings
- 7 days ago - Organigram Global Slides: Q3 2026 - Filings
- 7 days ago - OGI Looks 44.6% Undervalued on GF Value⢠Amid Price-to-Sales Caution - GuruFocus
- 7 days ago - Organigram reports Q3 net revenue $105.78M vs. $70.79M last year - TheFly